Last updated
Liraglutide proved the acylated GLP-1 idea; semaglutide is the successor that stretched it from once-daily to once-weekly and larger average weight loss. They share a mechanism and a maker — the differences are in engineering, dosing, and how they perform head-to-head.
Research reference only. Not medical advice, prescribing guidance, or a product recommendation.
| Dimension | Semaglutide | Liraglutide |
|---|---|---|
| Generic name | Semaglutide | Liraglutide |
| Brand names | Ozempic · Wegovy · Rybelsus | Victoza · Saxenda |
| Developer | Novo Nordisk | Novo Nordisk |
| Receptor target | GLP-1R (mono-agonist) | GLP-1R (mono-agonist) |
| Dosing | Once weekly (injectable) · daily oral (Rybelsus) | Once daily (injectable) |
| Half-life | ~168 h | ~13 h |
| Acylation | C18 fatty-diacid + Aib8, Arg34 | C16 palmitic acid + Arg34, via γGlu spacer |
| Backbone | GLP-1 analog, 31 residues | GLP-1(7-37) analog |
| Approved: T2D | Yes (Ozempic 2017; oral Rybelsus 2019) | Yes (Victoza 2010) |
| Approved: obesity | Yes (Wegovy 2021, 2.4 mg) | Yes (Saxenda 2014, 3.0 mg) |
| CV outcome trial | SUSTAIN-6 · SELECT (MACE reduction) | LEADER (MACE reduction) |
| Molecular weight | 4113.6 Da | 3751.2 Da |
Both drugs solve the same problem — native GLP-1 lasts only minutes — the same way: a fatty-acid chain that binds reversibly to albumin, plus substitutions that resist the DPP-4 enzyme. Liraglutide (2010) was the proof of concept, carrying a C16 palmitic-acid chain on a glutamate spacer that stretched GLP-1’s half-life to about 13 hours — enough for once-daily injection.
Semaglutide is that same strategy pushed harder: a longer C18 fatty-diacid, an Aib substitution at position 8 to further blunt DPP-4, and a linker tuned for tighter albumin binding. The result is a ~1-week half-life — once-weekly dosing — and, at obesity doses, meaningfully larger weight loss. Semaglutide also reaches where liraglutide cannot: an oral tablet (Rybelsus), something a daily-injection molecule never offered.
−15.8% (sema) vs −6.4% (lira)
Mean body-weight change (obesity, no diabetes) · n=338 · 68 wk — Rubino et al., JAMA 2022 — direct head-to-head; semaglutide superior
HbA1c −1.7 vs −1.0% · weight −5.8 vs −1.9 kg
HbA1c & weight (type 2 diabetes) · n=577 · 30 wk — Open-label; semaglutide superior on both
13% MACE reduction vs placebo
MACE (CV outcome) · n=9340 · ~3.8 yr — Established liraglutide’s cardiovascular benefit in T2D
20% MACE reduction vs placebo
MACE in obesity without diabetes · n=17604 · ~5 yr — Extended CV benefit to obesity without diabetes
Where the two have been compared directly — STEP 8 in obesity and SUSTAIN 10 in type 2 diabetes — once-weekly semaglutide produced greater weight loss and larger HbA1c reductions than once-daily liraglutide. Both carry proven cardiovascular-outcome data (LEADER for liraglutide; SUSTAIN-6 and SELECT for semaglutide). Liraglutide remains a used medicine and the historical bridge to the weekly era; semaglutide is the more potent successor. These are population means from trials, not predictions for any individual.
Both are acylated GLP-1 receptor agonists from Novo Nordisk that work by the same mechanism. Liraglutide is dosed once daily (half-life ~13 hours); semaglutide was engineered — a longer fatty-acid chain and an additional DPP-4-resistant substitution — for once-weekly dosing and, at obesity doses, larger average weight loss.
In the head-to-head STEP 8 trial (68 weeks, obesity without diabetes), semaglutide 2.4 mg produced −15.8% mean body-weight change versus −6.4% for liraglutide 3.0 mg. Semaglutide was superior on the primary endpoint. Individual responses vary; these are population means.
Victoza (liraglutide) and Ozempic (semaglutide) are the diabetes doses; Saxenda (liraglutide 3.0 mg) and Wegovy (semaglutide 2.4 mg) are the higher obesity doses. Within each brand pair the compound is the same; dose and FDA indication differ.
Semaglutide is — as oral Rybelsus for type 2 diabetes. Liraglutide is injectable only. Both injectable forms are subcutaneous.
Yes. Liraglutide: Victoza (T2D, 2010) and Saxenda (obesity, 2014). Semaglutide: Ozempic (T2D, 2017), Rybelsus (oral T2D, 2019), and Wegovy (obesity, 2021). This page is a research and educational reference, not medical advice.
Mechanism, evidence, and trade-offs between Semaglutide and Liraglutide — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.